Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:LEGN NASDAQ:MTSR NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.55$12.04$6.55▼$13.54$1.52B1.251.77 million shs971,496 shsLEGNLegend Biotech$31.96-1.2%$34.17$27.34▼$47.79$5.90B0.231.42 million shs891,763 shsMTSRMetsera$52.99+0.2%$41.37$12.30▼$54.47$5.57BN/A3.54 million shs1.12 million shsPCVXVaxcyte$42.39-2.8%$34.60$27.66▼$116.53$5.50B1.122.17 million shs1.44 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+2.48%-10.40%+33.84%+60.86%LEGNLegend Biotech0.00%+0.82%-9.10%-23.15%-27.40%MTSRMetsera0.00%+0.23%+47.60%+24.07%+5,298,999,900.00%PCVXVaxcyte0.00%-3.00%+30.07%+17.07%-64.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.55$12.04$6.55▼$13.54$1.52B1.251.77 million shs971,496 shsLEGNLegend Biotech$31.96-1.2%$34.17$27.34▼$47.79$5.90B0.231.42 million shs891,763 shsMTSRMetsera$52.99+0.2%$41.37$12.30▼$54.47$5.57BN/A3.54 million shs1.12 million shsPCVXVaxcyte$42.39-2.8%$34.60$27.66▼$116.53$5.50B1.122.17 million shs1.44 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+2.48%-10.40%+33.84%+60.86%LEGNLegend Biotech0.00%+0.82%-9.10%-23.15%-27.40%MTSRMetsera0.00%+0.23%+47.60%+24.07%+5,298,999,900.00%PCVXVaxcyte0.00%-3.00%+30.07%+17.07%-64.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.67Moderate Buy$13.0012.55% UpsideLEGNLegend Biotech 2.73Moderate Buy$66.56108.25% UpsideMTSRMetsera 2.38Hold$55.755.21% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25150.65% UpsideCurrent Analyst Ratings BreakdownLatest AUPH, LEGN, PCVX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.0010/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.0010/14/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/9/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$78.00 ➝ $76.0010/8/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MTSRMetseraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/7/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.009/30/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$54.009/27/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$260.11M5.84$0.31 per share37.45$2.68 per share4.31LEGNLegend Biotech$627.24M9.40N/AN/A$5.70 per share5.61MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4326.8620.63N/A23.31%20.06%13.81%11/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)Latest AUPH, LEGN, PCVX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A11/6/2025Q3 2025AUPHAurinia Pharmaceuticals$0.17N/AN/AN/A$67.70 millionN/A11/4/2025Q3 2025PCVXVaxcyte-$1.23N/AN/AN/AN/AN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 million7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63LEGNLegend Biotech0.304.714.57MTSRMetseraN/A5.265.26PCVXVaxcyteN/A11.1111.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%LEGNLegend Biotech70.89%MTSRMetseraN/APCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%LEGNLegend Biotech0.02%MTSRMetseraN/APCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.82 million125.80 millionOptionableAUPH, LEGN, PCVX, and MTSR HeadlinesRecent News About These CompaniesTD Asset Management Inc Purchases 236,188 Shares of Vaxcyte, Inc. $PCVXOctober 18 at 4:29 AM | marketbeat.comVaxcyte price target lowered to $85 from $160 at BTIGOctober 16 at 12:15 PM | msn.comWeiss Ratings Reiterates "Sell (D-)" Rating for Vaxcyte (NASDAQ:PCVX)October 16 at 2:19 AM | americanbankingnews.comVaxcyte, Inc. $PCVX Stock Holdings Increased by Aberdeen Group plcOctober 15, 2025 | marketbeat.comVaxcyte's (PCVX) Sell (D-) Rating Reiterated at Weiss RatingsOctober 14, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Shares Up 4.6% - Time to Buy?October 11, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on Vaxcyte (PCVX)October 8, 2025 | theglobeandmail.comVaxcyte Signs 15-Year Agreement with PatheonOctober 8, 2025 | theglobeandmail.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8, 2025 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 8, 2025 | marketbeat.comBank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)October 8, 2025 | finance.yahoo.com111 Capital Takes Position in Vaxcyte, Inc. $PCVXOctober 6, 2025 | marketbeat.comWhat Does Wall Street Think About Vaxcyte (PCVX)?September 30, 2025 | insidermonkey.comVaxcyte teams up with Thermo Fisher to ensure future vaccine productionSeptember 30, 2025 | msn.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in ...September 30, 2025 | finance.yahoo.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and ServicesSeptember 30, 2025 | globenewswire.comVaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine StudySeptember 30, 2025 | msn.comBanque Pictet & Cie SA Has $2.71 Million Stock Holdings in Vaxcyte, Inc. $PCVXSeptember 27, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Stake Cut by Assenagon Asset Management S.A.September 27, 2025 | marketbeat.comWe're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn RateSeptember 23, 2025 | finance.yahoo.comStrs Ohio Buys Shares of 16,600 Vaxcyte, Inc. $PCVXSeptember 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUPH, LEGN, PCVX, and MTSR Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$11.55 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.38 -0.17 (-1.43%) As of 10/17/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Legend Biotech NASDAQ:LEGN$31.96 -0.40 (-1.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$32.18 +0.22 (+0.69%) As of 10/17/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Metsera NASDAQ:MTSR$52.99 +0.13 (+0.25%) As of 10/17/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$42.39 -1.20 (-2.75%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$42.36 -0.02 (-0.06%) As of 10/17/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
